Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharvaris Announces Phase 3 Design for RAPIDe-3 Study and Presents HAE Study Data
Details : PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor, which is being evaluated for the treatment of hereditary angioedema attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Lifted Clinical Hold on Deucrictibant for HAE Attack Prophylactic Treatment
Details : PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. It is being evaluated in phase 2/3 trials for the prophylactic treatment of HAE Attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2024
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
Details : PHVS416 (deucrictibant) is an investigational softgel immediate-release capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, which is investigated for HAE attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2023
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : General Atlantic
Deal Size : $70.0 million
Deal Type : Private Placement
Pharvaris Announces $70 Million Private Placement Financing
Details : Pharvaris will use the net proceeds to fund research and development of its drug candidates including, PHVS416 (deucrictibant), a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, being developed for h...
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 20, 2023
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : General Atlantic
Deal Size : $70.0 million
Deal Type : Private Placement
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHVS416 (deucrictibant) is a bradykinin B2 receptor inhibitor small molecule drug candidate in oral soft gel capsule form for prophylaxis against hereditary angioedema.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pharmacokinetic properties of PHA121 were evaluated to support the intended therapeutic use of PHVS719 for the prophylactic treatment of HAE attacks using preclinical and clinical experimental models.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharvaris Participates in the Kinin 2022 Conference
Details : PHVS416 (PHA121) is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : PTC Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Risdiplam demonstrated statistically significant and medically meaningful motor milestone improvement in infants with Type 1 SMA
Product Name : Evrysdi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2020
Lead Product(s) : Risdiplam
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : PTC Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable